8 results about "Cathepsin Y" patented technology

The invention discloses a Jinhua ham taste optimization method based on metabonomics and an enzyme activity regulation and control technology. The method belongs to the field of meat quality control, and comprises the following optimization steps: carrying out sensory scoring on samples in different processing stages, and carrying out non-targeted analysis by using hydrophilic interaction liquid chromatography and MS / MS; analyzing and mining the metabonomics data; screening out differential metabolites in the processing process by applying a significance analysis p value, a difference multiple and a variable weight value; combining activity change results of cathepsin B and cathepsin L in the processing process; the activity of cathepsin B and cathepsin L is regulated and controlled by using a PF-DBO optimization algorithm, samples are collected and analyzed, and the influence of enzyme activity change and the change of the enzyme activity change on the content of the characteristic taste marker are evaluated. By precisely regulating and controlling the activity of cathepsin B and cathepsin L, the problem of complex relationship between taste substance change and cathepsin activity in the Jinhua ham processing process is solved; the control strategy enables the overall quality of the Jinhua ham to be significantly improved.

The present invention relates to a cathepsin K inhibitor comprising or consisting of Formula (I) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (I), wherein (X1) is the amino acid K; (X2) is an amino acid selected from R and W, and is preferably R; (X3) is an amino acid selected from R and W, and is preferably R; (X4) is the amino acid L; (X5) is an amino acid selected from Y, V and W, and is preferably V or Y, and is most preferably V; (X6) is an amino acid selected from I, M, L, W and R, and is preferably I, L or W; and is most preferably I; (X7) is an amino acid selected from H, W, A T, R; and is preferably H or R, and is most preferably R; and (Y) is a Michael acceptor. The present invention also relates to a cathepsin L inhibitor comprising or consisting of Formula (II) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (II), wherein (X1) is the amino acid K; (X2) is the amino acid R; (X3) is an amino acid selected from R, L and M, and is preferably L; (X4) is an amino acid selected from L, W, F and Y, and is preferably W; (X5) is an amino acid selected from V, H and R, and is preferably V; (X6) is an amino acid selected from M, L, I, W and R, and is preferably L; (X7) is an amino acid selected from W, A T, R; and is preferably W; and (Y) is a Michael acceptor.

The invention relates to synthetic peptides of no more than 20 amino acids in size useful in the treatment of cancer.

The present invention relates to a cathepsin K inhibitor comprising or consisting of Formula (I) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (I), wherein (X1) is the amino acid K; (X2) is an amino acid selected from R and W, and is preferably R; (X3) is an amino acid selected from R and W, and is preferably R; (X4) is the amino acid L; (X5) is an amino acid selected from Y, V and W, and is preferably V or Y, and is most preferably V; (X6) is an amino acid selected from I, M, L, W and R, and is preferably I, L or W; and is most preferably I; (X7) is an amino acid selected from H, W, A T, R; and is preferably H or R, and is most preferably R; and (Y) is a Michael acceptor. The present invention also relates to a cathepsin L inhibitor comprising or consisting of Formula (II) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (II), wherein (X1) is the amino acid K; (X2) is the amino acid R; (X3) is an amino acid selected from R, L and M, and is preferably L; (X4) is an amino acid selected from L, W, F and Y, and is preferably W; (X5) is an amino acid selected from V, H and R, and is preferably V; (X6) is an amino acid selected from M, L, I, W and R, and is preferably L; (X7) is an amino acid selected from W, A T, R; and is preferably W; and (Y) is a Michael acceptor.

The present invention concerns a particular crystalline freebase form of 2-(4-chlorobenzylamino)-4-(4-tert-butylaminopiperidin-1-yl)-quinoline. It also relates to a pharmaceutical composition and a kit of parts comprising such a crystalline freebase form and their use in treating and / or preventing cancers, fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases.

Populations of CAR T cells that exhibit reduced trogocytosis are disclosed, as well as methods for making such cells and methods of using such cells in the treatment of cancer. A reduction in trogocytosis is achieved by inhibiting Cathepsin B in the CAR T cells and / or inducing ubiquitylation of cancer antigens taken up by the CAR T cells.

Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and / or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and / or prevention of cell and / or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

To provide novel methods for antibody characterization sequencing.SOLUTION: Provided is a method for cleaving an antibody, comprising: mixing the antibody with cathepsin L, cathepsin D, or a combination of cathepsin L and cathepsin D to obtain one or more antibody fragments, the antibody comprising a light chain comprising a light chain variable region (VL) and a light chain constant region (CL) and a heavy chain comprising a heavy chain variable region (VH) and a heavy chain constant region (CH), and the cathepsin L and / or D cleaving the antibody between the VL and CL regions and / or between the VH and CH regions to create VL and / or VH antibody fragments and CL and / or CH antibody fragments; and optionally isolating one or more of the antibody fragments after the cleavage.SELECTED DRAWING: Figure 8